Lenalidomide, Bortezomib, and Dexamethasone with Transplantation in Myeloma.

BACKGROUND: High-dose chemotherapy with autologous stem cell transplantation has been the standard treatment for young patients with newly diagnosed myeloma. However, promising emerging data with the combination of lenalidomide, bortezomib and dexamethasone (RVD) have raised questions about the role...

詳細記述

保存先:
書誌詳細
出版年:N Engl J Med
主要な著者: Attal, Michel, Lauwers-Cances, Valerie, Hulin, Cyrille, Leleu, Xavier, Caillot, Denis, Escoffre, Martine, Arnulf, Bertrand, Macro, Margaret, Belhadj, Karim, Garderet, Laurent, Roussel, Murielle, Payen, Catherine, Mathiot, Claire, Fermand, Jean Paul, Meuleman, Nathalie, Rollet, Sandrine, Maglio, Michelle E., Zeytoonjian, Andrea A., Weller, Edie A., Munshi, Nikhil, Anderson, Kenneth C., Richardson, Paul G., Facon, Thierry, Avet-Loiseau, Hervé, Harousseau, Jean-Luc, Moreau, Philippe
フォーマット: Artigo
言語:Inglês
出版事項: 2017
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6201242/
https://ncbi.nlm.nih.gov/pubmed/28379796
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1611750
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料